BioWorld Asia

March 8, 2006

NicOx Shares Soar On Pfizer Deal For Ophthalmic Drugs

The French firm NicOx SA stands to break the bank, to the tune of up to nearly $400 million, per terms of a technology deal with Pfizer Inc. (BioWorld International) Read More

Basilea Shares Hit Peak On Positive Ceftobiprole Data

Antisense RNA Therapy Shows Promise In Muscular Dystrophy

GTC Biotherapeutics’ ATryn Gets Negative Vote In Europe

Positive Results For ATL-104 Have Alizyme Thinking Ahead

Diabetica To Receive Up To $41M Through Amylin Deal

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 16, 2026.

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

News in brief

BioWorld Asia

BioWorld Asia briefs for March 17, 2026

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...